信用证审单标准解读UCP600第13条权义分析/居松南

作者:法律资料网 时间:2024-07-04 19:23:35   浏览:8557   来源:法律资料网
下载地址: 点击此处下载
UCP600定义的审单标准解读

居松南


Article 14 Standard for Examination of Document

a. A nominated bank acting on its nomination, a confirming bank, if any, and the issuing bank must examine a presentation to determine, on the basis of the documents alone, whether or not the documents appear on their face to constitute a complying presentation.
a. 按照指定行事的被指定银行、保兑行(如有)以及开证行必须对提示的单据进行审核,并仅以单据为基础,以决定单据在表面上看来是否构成相符提示。

  本条款通过此项规定至少包含了以下含义。一是有义务同时也有权利进行单据审核的主体是哪些当事方。按照此条规定,则被指定银行、保兑行以及开证行。就被指定银行而言,其享有审核单据的义务在于,被指定银行必须依据单证是否相符来决定其履行兑付的义务。在此条上,我们必须再行强调,依据UCP600的规定,仅仅接受指定而非承担兑付义务的银行非是本条意义下的被指定银行。只有严格接受开证行的指定并承担兑付义务的被指定银行才有权利,也才有义务就单据进行审核。保兑行和开证行的义务是同等的,保兑行和开证行都是第一性的付款银行,其是否承担付款义务取决于所接受的单据是否符合开证行所开立的信用证的明确约定。
  此条款的第二项含义,是确立了审核单据的原则和标准。即上述银行仅仅能依据单据表面来决定单据是否符合信用证的要求。这是单据独立性的核心体现,国际贸易的多样性决定着单据的复杂多样,相关当事方特别是相应的银行仅仅能依据所接受的单据表面来判定是否和信用证规定相符。这同时也是信用证独立性原则的体现,信用证交易被视为和实际交易之外的独立交易,信用证交易的实现与否与实际交易之间是两个不同的法律关系,开证行等依据单据来履行付款义务,而贸易合同当事方则依据其他来承担义务享有权利。

b. A nominated bank acting on its nomination, a confirming bank, if any, and the issuing bank shall each have a maximum of five banking days following the day of presentation to determine if a presentation is complying. This period is not curtailed or otherwise affected by the occurrence on or after the date of presentation of any expiry date or last day for presentation.
b. 按照指定行事的被指定银行、保兑行(如有)以及开证行,自其收到提示单据的翌日起算,应各自拥有最多不超过五个银行工作日的时间以决定提示是否相符。该期限不因单据提示日适逢信用证有效期或最迟提示期或在其之后而被缩减或受到其它影响。
  UCP600在此条中明确了审单的合理期限,就此点规定而言,远比UCP500有了长足进步,将审单的时间期限限定为5个银行工作日。5个银行工作日的规定有助于减少争议。对此项规定的违反则直接导致拒付无效的法律后果。

c. A presentation including one or more original transport documents subject to articles 19, 20, 21, 22, 23, 24 or 25 must be made by or on behalf of the beneficiary not later than 21 calendar days after the date of shipment as described in these rules, but in any event not later than the expiry date of the credit.
c. 提示若包含一份或多份按照本惯例第19条、20条、21条、22条、23条、24条或25条出具的正本运输单据,则必须由受益人或其代表按照相关条款在不迟于装运日后的二十一个公历日内提交,但无论如何不得迟于信用证的到期日。
  此条规定设定了单据提交的期限。从这个角度而言,是针对受益人而做出的要求,即受益人应当提交运输单据的时间期限为21天。值得注意的是,这项规定中所称的运输单据应当指UCP600在19-25条中所规定的海运、空运、陆路等形式的单据。信用证的到期日在本条中是一个时间界限,无论如何上述单据的提交期间是不能超过信用证的有效期的,超过信用证有效期的单据提交构成单据的绝对不符。笔者认为,该条规定实际上表明迟于信用证有效期提交的单据根本无须开证行或其他相关银行做出单据不符的判定。

d. Data in a document, when read in context with the credit, the document itself and international standard banking practice, need not be identical to, but must not conflict with, data in that document, any other stipulated document or the credit.
d. 单据中内容的描述不必与信用证、信用证对该项单据的描述以及国际标准银行实务完全一致,但不得与该项单据中的内容、其它规定的单据或信用证相冲突。
  此条规定是对单据日期的合理判定。单据显示的日期实质上是反应了单据所指行为的发生日期,就各类单据而言,并不一定要求这些单据的时间完全一致,但是明显矛盾的单据日期将被判定为单据的不符。比如检验证书的检验日期比装船日期晚是无论如何不能做出合理解释的。

e. In documents other than the commercial invoice, the description of the goods, services or performance, if stated, may be in general terms not conflicting with their description in the credit.
e. 除商业发票外,其它单据中的货物、服务或行为描述若须规定,可使用统称,但不得与信用证规定的描述相矛盾。
  信用证在开立时一般会对货物描述做出详细约定,大抵有货物名称、数量、型号、金额、卖头等等。商业发票作为最完整体现货物信息的单据,当然应和信用证完全一致才能得出单证相符的结论。但是在其他单据上渴求和商业发票一致的货物描述显然是多余的,比如提单上无须现实具体的型号,无须显示金额,原产地证书上也无须做出此项全部要求。如果单据之间产生矛盾,则将被判定为单证不符,是UCP600所不接受的。所以就货物描述而言,使用简称等应当保证和商业发票即信用证的一致性。

f. If a credit requires presentation of a document other than a transport document, insurance document or commercial invoice, without stipulating by whom the document is to be issued or its data content, banks will accept the document as presented if its content appears to fulfil the function of the required document and otherwise complies with sub-article 14 (d).
f. 如果信用证要求提示运输单据、保险单据和商业发票以外的单据,但未规定该单据由何人出具或单据的内容。如信用证对此未 做规定,只要所提交单据的内容看来满足其功能需要且其它方面与十四条(d)款相符,银行将对提示的单据予以接受。
  UCP600下的单据标准严格按照独立性、表面性的原则做出规范要求。UCP60对几类最为重要的单据如发票、运输单据、保险单据做出了明确要求,限定了单据的要求。但对于这几类单据意外的单据则依据表面一致的原则来确定是否和信用证规定要求,只要提示的相关单据满足了信用证的描述,而且这类描述应当是依据单据表面可以判定的描述时,此类单据都将被视为符合信用证的要求。在此条款的意义下,对贸易双方约定的其他单据在信用证中应当做出明确规定,否则基本符合信用证要求的单据都是信用证银行可以接受的单据。

g. A document presented but not required by the credit will be disregarded and may be returned to the presenter.
g. 提示信用证中未要求提交的单据,银行将不予置理。如果收到此类单据,可以退还提示人。
  UCP600就当事人提交的未做要求的信用证授权银行可以不予理会。同时赋予银行可以将单据退还的行为。但是在UCP600中并未规定,如果此类单据中出现和其他单据不相符合的描述如何判定单证相符的问题。笔者认为,单据是否符合信用证的规定通过两个标准来判断,首先是单据和信用证的比对,其次是单据之间的校核,如果单据之间出现不相符合的情况将同样被视为单证不符。所以此项规定是授权银行可以不予理会的权利,但是选择是否理会的权利应当在银行,银行同样可以决定接受此类单据,并将其和其他单据进行比对,因此类单据出现的差异同样应当可以被认定单据不符合信用证的规定。从这个意义上来讲,多此一举的单据提交有可能导致画蛇添足,引起不必要的纷争。

h. If a credit contains a condition without stipulating the document to indicate compliance with the condition, banks will deem such condition as not stated and will disregard it.
h. 如果信用证中包含某项条件而未规定需提交与之相符的单据,银行将认为未列明此条件,并对此不予置理。
  UCP600要求单据必须是可以制作且可以一举信用证规定进行表面审核的单据,UCP600不接受进对某行为进行为进行约定,而没有就该行为的表现形式—单据做出约定的开证条款。如果信用证的相关条款未对其要求以单据的行使予以要求,相关银行将不予理会。这也再次体现了信用证单证相符的判定标准必须是依据单据表面的核心原则。

i. A document may be dated prior to the issuance date of the credit, but must not be dated later than its date of presentation.
i. 单据的出单日期可以早于信用证开立日期,但不得迟于信用证规定的提示日期。
  UCP600许可单据的出具日期早于开立日期,这符合国际贸易惯例,国际贸易行为当中最后一刻开立信用证的情况极为多见,而此时受益人早已完成了相关实际行为,故单据早于信用证开证日期是合理的。但是UCP600禁止单据的出单日期迟于提示日期,从逻辑上来看,单据提示时所有的单据应当制作完成,单据的日期迟于提示日期会被判定为单证的不符。

j. When the addresses of the beneficiary and the applicant appear in any stipulated document, they need not be the same as those stated in the credit or in any other stipulated document, but must be within the same country as the respective addresses mentioned in the credit. Contact details (telefax, telephone, email and the like) stated as part of the beneficiary’s and the applicant’s address will be disregarded. However, when the address and contact details of the applicant appear as part of the consignee or notify party details on a transport document subject to articles 19, 20, 21, 22, 23, 24 or 25, they must be as stated in the credit.
j. 当受益人和申请人的地址显示在任何规定的单据上时,不必与信用证或其它规定单据中显示的地址相同,但必须与信用证中述及的各自地址处于同一国家内。用于联系的资料(电传、电话、电子邮箱及类似方式)如作为受益人和申请人地址的组成部分将被不予置理。然而,当申请人的地址及联系信息作为按照19条、20条、21条、22条、23条、24条或25条出具的运输单据中收货人或通知方详址的组成部分时,则必须按照信用证规定予以显示。
  UCP600在申请人和受益人的地址上未采用镜像原则。所谓镜像原则要求单据和信用证的规定完全一致,如同镜子的物体和实物一样。在信用证纠纷中多次出现因打印字母错误等而产生的不符点争议。UCP600通过此条明确对地址等信息做出了忍让,毕竟当事人地址联系人等发生变更是正常的,同时当事人的某个字母出现错误的情况不应作为单证不符的借口。但是对于运输单据而言,UCP600提出了严格的要求,运输单据中的收货方、通知方是极为重要的当事人信息,该信息的准确与否会决定着物权能否真正归属与确定的当事人。如果信用证就上述方的信息做出了明确要求,则此类单据必须严格按照信用证的要求完成,否则直接导致单证不符的法律后果。

k. The shipper or consignor of the goods indicated on any document need not be the beneficiary of the credit.
下载地址: 点击此处下载

Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim)

State Food and Drug Administration General Administration of Customs of the People’s Republic of China


Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim)




(SFDA Decree No. 25)

The Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim), adopted by the State Food and Drug Administration, the General Administration of Customs of the People’s Republic of China and the General Administration of Sport of China, is hereby promulgated in the decree sequence number of the State Food and Drug Administration and shall come into force as of September 1, 2006.


Shao Mingli
Commissioner
State Food and Drug Administration

Mou Xinsheng
Minister
General Administration of Customs of the People’s Republic of China

Liu Peng
Minister
General Administration of Sport of China
July 28, 2006





Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim)


Article 1 The Provisions are formulated with a view to standardizing the administration of import and export of anabolic agents and peptide hormones in accordance with the Drug Administration Law of the People’s Republic of China, Customs Law of People's Republic of China, Anti-doping Regulations and other relevant laws and administrative regulations.

Article 2 The State adopts license control on the import and export of anabolic agents and peptide hormones.

Article 3 The importer shall apply for the importation of anabolic agents and peptide hormones to the State Food and Drug Administration.

Article 4 For the importation of anabolic agents and peptide hormones for medical purpose, the importers shall submit the following materials:
(1) Application Form for Drug Import;
(2) Copy of the purchasing contract or order form;
(3) Copy of the Import Drug License (or the Pharmaceutical Product License) (original or duplicate);
(4) Copy of the Drug Supply Certificate, Business License for Enterprises as a Legal Person, Qualification Certificate for Import and Export Enterprise (or Foreign Trade Operator Filing and Registration Form) and Organization Code Certificate of the importer; to import drug substance and intermediate preparations including preparations to be repackaged in China for their own needs, drug manufacturers shall submit copies of the Drug Manufacturing Certificate, Corporate Business License and Organization Code Certificate;
(5) Where holders of the Import Drug License (or the Pharmaceutical Product License) entrust other companies to export their drugs, they shall provide the authorization letter for export.

All copies mentioned above should be stamped with the official seal of the importer.

Article 5 For the importation of anabolic agents and peptide hormones for teaching and scientific research purposes, the importers shall submit the following materials:
(1) Application Form for Drug Import;
(2) Copy of the purchasing contract or order form;
(3) Certificates of legitimate qualifications of users in China, calculation basis for the quantity of the drug in use and letter of guarantee issued by the user for legitimate use and management of the drug;
(4) Approval documents for relevant scientific research projects or approval documents of relevant competent authority;
(5) Where entrusted by users for importation, importers shall provide copies of the authorization agreement, the Business License for Enterprises as a Legal Person, Qualification Certificate for Import and Export Enterprise (or Foreign Trade Operator Filing and Registration Form) and Organization Code Certificate of the importers.

All copies mentioned above should be stamped with the official seal of the importer.

Article 6 Where a enterprise in China entrusted by an overseas enterprise for contract manufacturing needs to import anabolic agents and peptide hormones, it shall provide materials required in Items (1), (3) and (5) of Paragraph 1 of Article 5, in addition, official documents to prove recorded by the local (food and) drug regulatory department of the province, autonomous region or municipality directly under the Central Government.

All copies mentioned above should be stamped with the official seal of the importer.

Article 7 The State Food and Drug Administration shall decide whether or not to approve the import within 15 working days after receiving the application for import and the relevant materials. Where the application is approved, the State Food and Drug Administration shall issue the Import License for the drug; where the application is not approved, the State Food and Drug Administration shall give reasons in writing.

Article 8 The importer may declare to the customs of the ports where drug importation is permitted upon presenting the Import License for the drug issued by the State Food and Drug Administration. The customs shall clear the drug in the presence of the Import License for the drug.
The Drug Import Note is not required for import of anabolic agents and peptide hormones.

Article 9 To import anabolic agents and peptide hormones including those sold in China for the first time for medical purpose, the importer shall fill in the Import Drug Clearance Form timely after going through the import formalities and submit the following materials in duplicate to the (food and) drug regulatory department where the port of entry is located, upon presenting the original Import Drug License (or the Pharmaceutical Product License) (original or duplicate) and the original Import License for the drug, to apply for the Notice of Import Drug Port Test:
(1) Copies of the Import Drug License (or Pharmaceutical Product License) (original or duplicate) and the Import License for the drug;
(2) Copies of the Drug Manufacturing Certificate or Drug Supply Certificate, and Copy of the Business License for Enterprises as a Legal Person.
(3) Copy of the certificate of origin;
(4) Copy of the purchasing contract;
(5) Copies of packing list, bill of lading and freight invoice;
(6) Copy of the certificate of analysis;
(7) Format of drug insert sheet, package and label (except for drug substance and intermediate preparation);

All copies mentioned above should be stamped with the official seal of the importer.

Article 10 After checking the received Import Drug Clearance Form and relevant materials, the port (food and) drug regulatory department shall return the original Import Drug License (or Pharmaceutical Product License) (original or duplicate) and the original Import License for the drug to the importer, and send the Notice of Import Drug Port Test, along with a copy of the dossier as prescribed in Article 9 of the Provisions, to the port drug testing institute on the same day.

After receiving the Notice of Import Drug Port Test, the port drug testing institute shall contact the importer within two working days and conduct sampling on the storage site. Upon the completion of the sampling, the mark “sampled” shall be stamped on the back of the first page of the original Import License for the drug, with the seal of sampling institute affixed.

Article 11 Anabolic agents and peptide hormones imported for teaching and research purposes or for the domestic manufacturing contracted by overseas enterprises are exempted from testing.

Article 12 The port (food and) drug regulatory department shall report timely to the State Food and Drug Administration in any of the following circumstances:
(1) The port (food and) drug regulatory department refuses to issue the Notice of Import Drug Port Test in accordance with the provisions in Article 17 of the Provisions for Import Drug (Decree No. 4 of the State Food and Drug Administration and the General Administration of Customs);
(2) The port (food and) drug testing institute refuses the sampling in accordance with the requirements in Article 25 of the Provisions for Import Drug.

The port (food and) drug regulatory department shall take mandatory administrative measures to seal up or seize all the imported drugs within the situations prescribed in the previous paragraph. It shall make the decision of allowing shipping back within seven days from the date of the seal-up or seizure, and inform the importer of applying for the Export License for the drug according to the export procedures for anabolic agents and peptide hormones prescribed in the Provisions and return all the import drugs to the original exporting country.

Where the importer fails to respond or make clear its intention to ship back the drugs within ten days after being informed of the decision, the sealed up or seized drugs shall be destroyed under the supervision of the port (food and) drug regulatory department.

Article 13 For imported anabolic agents and peptide hormones out of specifications upon testing by the port drug testing institute, the importer shall provide a detailed report about the distribution and use of all the imported drugs to the port (food and) drug regulatory department where the importer is located within two days after receiving the Import Drug Test Report.

After receiving the Import Drug Test Report, the port (food and) drug regulatory departments shall take mandatory administrative measures to timely seal up or seize all the drugs and, within seven days, decide whether or not to place the case on file.

Where the importer fails to apply for a retesting within the specified timeline or the result of the retesting is still out of specifications, the port (food and) drug regulatory department shall make the decision of allowing shipping back and notify the importer to apply for the Export License for the drug according to export procedures for anabolic agents and peptide hormones prescribed in the Provisions to return all the imported drugs to the original exporting country. Where the importer fails to respond or make clear its intention to ship back the drugs within ten days from the date of receiving the decision, the drugs shall be destroyed under the supervision of the port (food and) drug regulatory department.

Where the result of retesting is in compliance with the specifications, the port (food and) drug regulatory department shall remove the mandatory administrative measures of seal-up and seizure.

The port (food and) drug regulatory department shall handle the case according to the provisions in Paragraph 2, Paragraph 3 and Paragraph 4 of this Article and report the result to the State Food and Drug Administration, and, at the same time, notify the (food and) drug regulatory departments of provinces, autonomous regions and municipalities directly under the Central Government as well as other port (food and) drug regulatory departments.

Article 14 Where domestic drug manufacturers, distributors and medical institutions purchase imported anabolic agents and peptide hormones, the supplier shall provide copies of the Import Drug License (or Pharmaceutical Product License), the Import License for the drug and the Import Drug Test Report, and affix its official seal to the abovementioned copies.

Article 15 The exporter shall apply for exportation of anabolic agents and peptide hormones to the (food and) drug regulatory department of the province, autonomous region or municipality directly under the Central Government, where it is located, and submit the following materials:
(1) Application Form for Drug Export;
(2) Original import permit (or its copy with notarization) provided by the drug regulatory authority of the importing country or region.
If the importing country or region has no license system in the importation of anabolic agents and peptide hormones, the exporter shall provide the official document (original) of the drug regulatory authority of the importing country or region to prove that the import of the drugs of this type is exempted from the import permit, along with one of the following documents:
a. Original official document (or its copy with notarization) granting import provided by the drug regulatory authority of the importing country or region;
b. Certificates of legitimate qualifications of importers and original supporting document (or its copy with notarization) proving legitimate use of the drug;
(3) Copy of the purchasing contract or order form (except for manufacturers that export their own products);
(4) Copy of the export contract or order form;
(5) Where the export drug is an approved one produced by a domestic manufacturer, the Drug Manufacturing Certificate and Business License for Enterprises as a Legal Person of the manufacturer and a copy of the approval document of the drug shall be provided;
Where the export drug is produced by a domestic enterprise under contract of an overseas enterprise, the exporter shall provide a copy of the official document to prove recorded by the local (food and) drug regulatory department of the province, autonomous region and municipality directly under the Central Government.
(6) Copies of the Business License for Enterprises as a Legal Person, Qualification Certificate for Import and Export Enterprise (or Foreign Trade Operator Filing and Registration Form) and Organization Code Certificate of the exporter.

All copies mentioned above should be stamped with the official seal of the exporter.

Article 16 Where the drugs are to be shipped back in accordance with the requirements in Article 12 and Article 13 of the Provisions, the exporter shall provide the following materials to apply for the Export License for the drug:
(1) Documents proving the request for return of goods made by the original exporter of the exporting country;
(2) Import License for the drug.

Article 17 The (food and) drug regulatory department of the province, autonomous region and municipality directly under the Central Government shall decide whether or not to approve the export within 15 working days after receiving the export application and relevant materials.

Where the application is approved, the regulatory department shall issue the Export License for the drug; where the application is not approved, the regulatory department shall give reasons in writing.

Where the Export License for the drug is applied for in accordance with the requirements in Article 16 of the Provisions, the issuing authority shall mark “return of the original goods” on the Export License for the drug.

Article 18 The exporter may go through the customs formalities upon presenting the Export License for the drug issued by the (food and) drug regulatory department of the province, autonomous region and municipality directly under the Central Government. The customs shall clear the drug in the presence of the Export License for the drug.

Article 19 The importer and exporter shall provide one more sheet of customs declaration form and apply for sign-back of the sheet when going through the customs formalities. The customs shall stamp the “proof seal” on the sheet in the presence of the Import License for the drug and Export License for the drug. The customs shall charge the cost according to the relevant regulations for issuing certificates.

The importer and exporter shall return the first sheet of the Import License for the drug or Export License for the drug along with the customs declaration form with the seal of the customs, to the issuing regulatory department within one month after completing the import and export.

Where the importer or exporter conducts no relevant importation or exportation after obtaining the Import License for the drug and Export License for the drug, the importer or exporter shall return the original license to the issuing regulatory department within one month after expiration of the license.

Article 20 The validation of the Import License for the drug is one year; the validation of the Export License for the drug is no more than three months (valid within the calendar year).

“One license for one customs clearance” is implemented for the Import License for the drug and Export License for the drug. The license shall be used only once within the validation and its content shall not be altered. Where the import or export is postponed for some reasons, the importer or exporter may request for a new license once with the original one.

Article 21 Where the Import License for the drug or Export License for the drug is lost, the importer or exporter shall report the loss to the original issuing authority in writing immediately. After receiving the loss report, the original issuing authority shall notify the port customs and reissue the license if no harmful consequences are found through confirmation.

Article 22 The Import License for the drug and Export License for the drug are uniformly printed by the State Food and Drug Administration.

Article 23 Where anabolic agents and peptide hormones are imported or exported in the form of processing trade, the customs shall go through and supervise the clearance formalities upon presentation of the Import License for the drug or Export License for the drug. Those not exported for special reasons shall be transferred to and handled by the local (food and) drug regulatory department in accordance with relevant regulations, and the customs shall conduct the verification and cancellation procedures in the presence of relevant documents.

Article 24 Anabolic agents and peptide hormones entering or leaving between bonded zones, export processing zones, other special Customs controlling areas, Customs bonded and controlling areas, with overseas, or between the special Customs controlling areas and the Customs bonded and controlling areas are exempt from application for the Import License for the drug or Export License for the drug, and supervised by the Customs.

Import License for the drug shall be applied for anabolic agents and peptide hormones entering from bonded zones, export processing zones, other special Customs controlling areas and Customs bonded and controlling areas into other places in China.

Export License for the drug shall be applied for anabolic agents and peptide hormones entering bonded zones, export processing zones, other special Customs controlling areas and Customs bonded and controlling areas from other places of China.

Article 25 Where an individual carries or mails anabolic agents and peptide hormones, within a reasonable amount, into or out of China for medical needs, the customs shall clear the drugs in the presence of prescriptions of medical institutions in accordance with relevant regulations on prescriptions of the competent health department.

Article 26 Besides prescribed in the Provisions, the importation, port test, supervision and control of anabolic agents and peptide hormones for medical purpose are implemented with reference to requirements related to drug importation in the Provisions for Drug Importation.

Article 27 Anabolic agents and peptide hormones imported for medical purpose mentioned in the Provisions refer to the import anabolic agents and peptide hormones to be used for preparation production or to be marketed in China.

Importer refers to the importer specified on the Import License for the drug obtained in accordance with the Provisions.

Exporter refers to the exporter specified on the Export License for the drug obtained in accordance with the Provisions.

Article 28 These Provisions shall go into effect as of September 1, 2006. The Notice on Import and Export of Anabolic Agents and Peptide Hormones (Guo Shi Yao Jian An [2004] No. 474) issued by the State Food and Drug Administration on September 30, 2004 shall be annulled therefrom.


厦门市人民代表大会常务委员会关于修改《厦门市荣誉市民称号授予办法》的决定

福建省厦门市人大常委会


厦门市人民代表大会常务委员会关于修改《厦门市荣誉市民称号授予办法》的决定

厦门市人民代表大会常务委员会公告

第25号

(2005年8月5日)

  《厦门市人民代表大会常务委员会关于修改<厦门市荣誉市民称号授予办法>的决定》已于2005年7月29日经厦门市第十二届人大常委会第二十一次会议通过。现予公布,自公布之日起施行。



厦门市人民代表大会常务委员会关于修改《厦门市荣誉市民称号授予办法》的决定

(2005年7月29日厦门市第十二届人民代表大会常务委员会第二十一次会议通过)

  厦门市第十二届人民代表大会常务委员会第二十一次会议,对《厦门市人民政府关于提请审议〈厦门市荣誉市民称号授予办法〉修正案(草案)的议案》进行了审议,决定对《厦门市荣誉市民称号授予办法》作如下修改:

  一、第二条修改为:“对热爱厦门,具有良好社会声誉并符合下列条件之一的港澳台同胞、华侨和外国人士,可授予‘厦门市荣誉市民’称号:

  (一) 促进海峡两岸交流和祖国统一,贡献突出的;

  (二) 热心资助本市发展社会公益事业和慈善事业,贡献突出的;

  (三) 积极为本市引进先进技术和人才、设备,促进本市高新技术发展,贡献突出的;

  (四) 积极为本市引进资金,促进基础设施建设,优化投资环境,贡献突出的;

  (五)积极为本市开拓国际市场,开展经贸活动,贡献突出的;

  (六) 促进本市发展对外交往,建立友好城市,开展交流合作,贡献突出的;

  (七) 积极为本市发展科学、教育、文化、卫生和体育事业,贡献突出的;

  (八) 其他方面对本市贡献突出的。”

  二、第三条第三款修改为:“上列行政主管部门收到申报后提出初审意见,并由市人民政府侨务行政主管部门汇总意见后,报市人民政府审核,由市人民政府提请市人民代表大会常务委员会审议决定。”

  三、删去第四条。

  四、第五条改为第四条,修改为:“市人民代表大会常务委员会公布授予‘厦门市荣誉市民’称号的决定后,市人民政府举行授予‘厦门市荣誉市民’称号的仪式,颁发证书、证章。证书、证章由市人民政府统一制作,证书由市长签署。”

  五、增加一条,作为第八条:“荣誉市民有下列情形之一的,经市人民政府提请,由市人民代表大会常务委员会决定撤销其‘厦门市荣誉市民’称号,并予以公布:

  (一)触犯法律,受到刑事追究的;

  (二)其他与荣誉市民称号不相称的行为并造成严重后果的。”

  六、第九条修改为:“本办法由市人民政府组织实施,在实施过程中,市人民政府可根据本市的实际和需要,作出具体规定,并报市人民代表大会常务委员会备案。”

  本决定自公布之日起施行。

  《厦门市荣誉市民称号授予办法》根据本决定作相应修改,并对条款顺序作相应调整,重新公布。